


# Author's Accepted Manuscript

Indirubin-3'-oxime suppresses human  
cholangiocarcinoma through cell-cycle arrest and  
apoptosis

Ming-Yang Lee, Yi-Zhen Li, Kao-Jean Huang,  
Hui-Chi Huang, Ching-Yen Lin, Ying-Ray Lee



PII: S0014-2999(18)30562-4  
DOI: <https://doi.org/10.1016/j.ejphar.2018.09.023>  
Reference: EJP71992

To appear in: *European Journal of Pharmacology*

Received date: 4 June 2018  
Revised date: 10 September 2018  
Accepted date: 25 September 2018

Cite this article as: Ming-Yang Lee, Yi-Zhen Li, Kao-Jean Huang, Hui-Chi Huang, Ching-Yen Lin and Ying-Ray Lee, Indirubin-3'-oxime suppresses human cholangiocarcinoma through cell-cycle arrest and apoptosis, *European Journal of Pharmacology*, <https://doi.org/10.1016/j.ejphar.2018.09.023>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Indirubin-3'-oxime suppresses human cholangiocarcinoma through cell-cycle arrest and apoptosis

Ming-Yang Lee<sup>1,5</sup>, Yi-Zhen Li<sup>2</sup>, Kao-Jean Huang<sup>3</sup>, Hui-Chi Huang<sup>4</sup>, Ching-Yen Lin<sup>2,\*</sup> and Ying-Ray Lee<sup>2,5,\*</sup>

<sup>1</sup> Departments of Hematology and Oncology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi 600, Taiwan. M-Y Lee; 05825@cych.org.tw

<sup>2</sup> Departments of Medical Research, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi 600, Taiwan. Y-Z Lee: seraphim9515@hotmail.com

<sup>3</sup> Institute of Biologics, Development Center for Biotechnology, New Taipei City 22180, Taiwan. K-J Huang: kj-huang@dcb.org.tw

<sup>4</sup> Development of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 40402, Taiwan. H-C Huang: hchuang@mail.cmu.edu.tw

<sup>5</sup> Departments of Nursing, Min-Hwei College of Health Care Management, Tainan 736, Taiwan.

\* Correspondence: Y-R Lee: yingray.lee@gmail.com Tel.: +886-5-2765041, ext. 5560; C-Y Lin: jouyuan22@gmail.com Tel.: +886-5-2765041, ext. 5578

### Abstract

Cholangiocarcinoma (CCA) is one of the most serious of all cancers and a major public health problem. CCA is an extremely invasive cancer, and the survival rate for CCA patients is only 24 months after diagnosis. Although surgery and chemotherapy can extend the survival rate to 5 years, <20-40% of CCA patients will survive this long; therefore, it is crucial to discover an effective chemotherapeutic agent for CCA. Indirubin-3'-oxime (I3O), a derivative of indirubin, has been shown to suppress cell proliferation and induce cell-cycle arrest and cell apoptosis in various human cancers. In this study, four human CCA cell lines—NOZ, HuCCT1, OCUG-1, and OZ—were used to evaluate the anticancer properties of I3O. Cell viability, cell-cycle arrest, and apoptosis were assessed using Western blotting, immunofluorescence, and flow cytometry analysis. The data show that I3O treatment can inhibit cell proliferation and induce cell-cycle arrest, and caspase-dependent apoptosis in CCA cells. These findings suggest that I3O could suppress tumor growth by regulating the cell cycle and inducing apoptosis, and is a potential therapeutic agent for treating human CCA.

Download English Version:

<https://daneshyari.com/en/article/11025724>

Download Persian Version:

<https://daneshyari.com/article/11025724>

[Daneshyari.com](https://daneshyari.com)